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Analysis of testosterone 
pulsatility in women with 
ovulatory menstrual cycles
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ABSTRACT
Objective:  To evaluate the pattern of the pulsatile secretion of testosterone in normal menstrual 
cycle. Methods: Eight healthy women with ovulatory menstrual cycles were enrolled. Blood 
samples were collected at ten-minute intervals for six hours, starting between 7 and 8 am, after 
a ten-hour fasting, in three phases: mid-follicular (Day 7), late follicular (Day 12) and mid-luteal 
phase (Day 21). Samples were assayed for testosterone, LH and the baseline also for SHBG. 
Results: Testosterone pulse frequency, mean amplitude pulse, percentage of increment in pulse 
amplitude, mean duration of pulses and pulse interval were similar in the three phases. LH pulsa-
tility was statistically different among the three phases (p < 0.001) representing normal ovulatory 
cycles. Conclusions: These data increase the knowledge about the testosterone secretion profile 
in the human menstrual cycle and can be used as a contribution to clinical investigation in both 
hyperandrogenism and androgen insufficiency syndrome. Arq Bras Endocrinol Metab. 2009;53(8):1040-6
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RESUMO
Objetivo: Avaliar o padrão pulsátil da secreção da testosterona em mulheres normais. Méto-
dos: Oito mulheres saudáveis com ciclos ovulatórios foram selecionadas. Amostras sanguí-
neas foram coletadas a cada dez minutos durante seis horas, começando entre 7 e 8 h da 
manhã, após dez horas de jejum, nas três fases do ciclo menstrual: folicular média (Dia 7), foli-
cular tardia (Dia 12) e lútea (Dia 21). Foram mensurados: testosterona, LH e, no basal, também 
SHBG. Resultados: A frequência dos pulsos de testosterona, média da amplitude do pulso, 
porcentagem do incremento da amplitude, duração e intervalos dos pulsos foram similares 
nas três fases (p > 0,05). A pulsatilidade do LH foi estatisticamente diferente entre as três fases 
(p < 0,001), caracterizando padrão característico do ciclo ovulatório normal. Conclusões: Esses 
dados aumentam o conhecimento sobre o padrão de secreção da testosterona no ciclo mens-
trual humano e representam uma contribuição para a investigação clínica, tanto no hiperandro-
genismo como na síndrome de insuficiência androgênica. Arq Bras Endocrinol Metab. 2009;53(8):1040-6
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InTRODUCTIOn
The women menstrual cycle involves a complex and regular change in female anatomy and physiology, 
that occurs every month, between puberty and meno-
pause, and results from the integrated function of the 
hypothalamus, pituitary, ovary and their effector’s sites. 
The ovarian steroidogenesis occurs at the granulosa 
and theca cells and varies according different phases of 
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menstrual cycle. The hormone synthesis depends on 
several factors, such as gonadotrophin levels and its re-
ceptors, level of precursor substrate for steroidogenesis 
and presence of specific enzymes (1,2). An essential fac-
tor for this regulation is the pulsatile pattern of gona-
dotrophin secretion by pituitary (3,4). 
Androgen synthesis by the ovaries occurs at the theca 
cells, and is mainly regulated by LH (5,6), but also by 
insulin (7,8). These androgens are transferred to the pre-
ovulatory granulosa cells, where the androstenedione 
and testosterone are aromatized to estrone and estradiol 
by 17-b-hydroxysteroid dehydrogenase type I, stimula-
ted by FSH (9). The ovarian androgen production and 
its conversion to estradiol are essential to the physiologic 
ovulatory process, and an insufficient androgen produc-
tion at the follicular phase can lead to anovulation (10). 
Some studies have shown fasting testosterone and 
androstenedione present some fluctuation in menstrual 
cycle with higher levels in follicular phase than in lute-
al phase, especially if cycles are ovulatory (11,12). The 
majority of the hormones is synthesized and secreted 
in a pulsatile pattern. A pulse is identified by an abrupt 
increase with a subsequent decrease in the hormone 
output, which reflects in its serum concentration (13). 
Although normal pulsatility of androgen secretion was 
demonstrated in men (14,15) as well as in some disea-
ses (16), the normal pulsatile pattern of secretion and 
its variability among the different phases of the mens-
trual cycle have not been established yet. 
An adequate androgen secretion is important to the 
follicle recruitment and selection but high androgenic 
levels can lead to anovulation (17) with changes in the 
pattern of secretion of gonadotrophins (18). Barontini 
and cols. (19) and Veldhuis and cols. (20) have suggested 
mechanism for pathogenesis of chronic anovulation and 
have shown disruption of the synchronous secretion of 
LH and testosterone in adolescents with polycystic ovary 
syndrome. Considering the related data and the actual fa-
cilities in prescribing testosterone for women by gyneco-
logists, it is important to know if there is any variation of 
this hormone secretion on distinct phases of the normal 
menstrual cycle, enhancing the knowledge of the woman 
physiology. Thus, the aim of this study was to analyze 
the pulsatile secretion profile of testosterone in different 
phases of ovulatory menstrual cycle in healthy women.
METhODS 
Eight young, healthy voluntary women were enrolled in 
this study. They were required to be between 18 and 30 
years-old, non-smokers and with menstrual cycles oc-
curring at regular intervals of 26 to 32 days. Menstrual 
cycles were considered as regular by menstrual recordings. 
The first day of menstrual bleeding was considered as 
the first day of the cycle. Ovulation was confirmed by 
serum progesterone level performed in the luteal phase 
(21st day of the cycle) above 5.0 ng/mL (21) of each 
studied cycle. In the 21st day of menstrual cycle, if pro-
gesterone levels were under 5.0 ng/mL, the cycle was 
considered as anovulatory and discharged. Volunteers 
with history or evidence of heart, liver, or kidney disea-
se, diabetes, menstrual or thyroid disorders, pregnancy, 
lactation and hypothalamic, pituitary or ovarian disor-
ders were excluded. All patients who were on any drugs 
which could influence menstrual cycle during last three 
months were also excluded. The protocol of this experi-
ment was approved by the Institutional Ethics Commit-
tee (UFRN), and all participants signed consent forms 
and received a full verbal and written description of the 
nature of the experiment, its risks and benefits and their 
ability to withdraw from the experiment at any time. 
Volunteers were screened through interviews, and a 
clinical examination by a physician was performed be-
fore inclusion in the study. Body mass index (BMI) was 
calculated as weight (kg) divided by the squared height 
(m2) (22). All women were kept on dietary and exercise 
previous habits as well as used a barrier contraception 
method (condom) during the period of the study. 
Experimental data collection
Considering the first day of menstrual cycle as Day 1, 
blood samples were collected in three phases: mid-folli-
cular (7th day of the cycle or Day 7), late follicular (Day 
12) and mid-luteal phase (Day 21). Blood samples were 
collected in three consecutive cycles for each subject 
and hematocrits above 35% were required. 
Blood samples were collected via a venous catheter at 
ten-minute intervals for six hours, starting between 7 and 
8 am, after a ten-hour of fasting (n = 37 points/subject). 
The subjects remained resting during the time of the ex-
periment and were permitted to drink water or juice and 
to eat fruits at least every two hours. Blood sample were 
centrifuged and sera were stored at -20 °C until assayed. 
hormone assays
Samples collected at ten-minute intervals were assayed 
for testosterone and LH, and the first sample (baseline) 
was also assayed for SHBG. Total testosterone deter-
mination was performed by radioimmunoassay (RIA), 
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with a “coat-a-count” kit (Diagnostic Products Cor-
poration, Los Angeles, CA, USA), and LH and SHBG 
levels were performed with chemoluminescent kits at 
Immullite® 2000 equipment (Diagnostic Products 
Corporation, Los Angeles, CA, USA).
Method sensitivities for LH, testosterone and SHBG 
were 0.05 mUI/mL, 4 ng/dL, and 0.02 nmol/L, res-
pectively. Samples for each subject were done at the same 
assay to minimize the interassay variation. The intra-as-
say coefficients of variation for these assays were 3.8% 
for the LH, 4.8% for testosterone, and 4.2% for SHBG. 
Free androgen index (FAI) was calculated from to-
tal testosterone and SHBG: FAI = (100 x testostero-
ne)/SHBG with both expressed in nanomoles per li-
ter. FAI results were analyzed in the different phases of 
menstrual cycle. LH pulsatility was studied to confirm 
normal pattern of the studied cycles. 
Data analysis
The time series of testosterone and LH concentrations 
over six hours were analyzed for mean concentration, 
pulse frequency, pulse amplitude, mean % amplitude 
elevation and pulse duration by the computer program 
Cluster, developed by Veldhuis and Johnson in 1986 at 
the University of Virginia. A 2x1 pulse configuration 
was used with up and down T-ratios of 2 to give a false 
detection rate less than 10%. 
Statistical analysis
Descriptive analysis was performed using GraphPad 
Prism, version 3.00 for Windows (GraphPad Softwa-
re, San Diego, CA, USA). All data sets were tested for 
non-normality. One-way ANOVA and Kruskal-Wallis 
tests were performed to compare the three phases of 
menstrual cycle. P-value less than 0.05 was considered 
statistically significant.
RESUlTS
Table 1 presents the characteristics of the subjects at the 
initial evaluation. Mean BMI was 21.33 ± 0.97 kg/m2 
and all volunteers had ovulatory menstrual cycles. 
Mean serum values of testosterone, LH, SHBG and 
FAI are shown in table 2. There was no statistically sig-
nificant difference in these parameters among the three 
menstrual cycle phases evaluated. 
LH pulsatility was statistically different among the 
three phases of the menstrual cycle (p < 0.001) with 
mean pulse frequency of 4.5 ± 1.51 in mid-follicular 
phase, 5.125 ± 1.35 in late follicular phase and 1.0 ± 
0.75 in luteal phase (Day 21) (Figure 1). Mean pul-
se interval was 66.39 ± 15.19 in mid-follicular phase, 
60.00 ± 17.43 in late follicular phase and 100.00 ± 
102.50 in the luteal phase (p = 0.02). There was no di-
fference among the three phases in LH mean amplitude 
pulse, percentage of increment in pulse amplitude and 
mean duration of pulses (Figure 1).
Figure 2 illustrates serum testosterone pulsatile se-
cretion profile in one of the eight ovulatory women, 
each of whom underwent repetitive blood sampling at 
ten-minute intervals in the mid-follicular (Day 7), late 
follicular (Day 12) and mid-luteal (Day 21) phase of 
menstrual cycle. Testosterone pulse frequency was si-
milar in the three phases, with a mean of 5.25 ± 0.70 
in the mid-follicular phase, 5.0 ± 0.92 in late follicular 
phase and 6.12 ± 1.45 in the luteal phase (p > 0.05) 
(Figure 3). There was also no difference among the 
three phases in testosterone mean amplitude pulse, 
percentage of increment in pulse amplitude and mean 
duration of pulses (Figure 3). Mean frequency of tes-
tosterone nadir was 5.25 in the mid-follicular phase, 
6.0 in late follicular phase and 6.25 in the luteal phase 
(p > 0.05). There was no difference in pulse interval and 
in nadir duration among the three phases (p > 0.05).
DISCUSSIOn
Ovarian function involves hormonal secretion, but also 
gametogenesis and ovulation. For this, a complex hor-
monal secretion and a coordinated relationship among 
Table 1. Clinical, biochemical and hormonal characteristics of the subjects at the 
initial evaluation
Characteristics Mean SD Reference range
Age (years) 23.25 2.37 –
Body mass index (kg/m2) 21.33 0.97 20.00 - 24.99
Glucose (mg/dL) 81.87 7.54 70.00 - 90.00
Urea (mg/dL) 23.5 6.2 15.00 - 40.00
Creatinin (mg/dL) 0.6 0.07 0.40 - 1.40
Aspartate aminotransferase (U/L) 20.2 4.7 0.00 - 31.00
Alanine aminotransferase (U/L) 19 6.5 0.00 - 31.00
Total protein (g/dL) 6.8 0.4 6.00 - 8.00
Albumin (g/dL) 4.1 0.3 4.00 - 6.00
Hematocrit (%) 39.87 1.55 36.00 - 40.00
TSH (mUI/mL) 2.23 1.3 0.4 - 4.0
Progesterone (ng/mL)* 12.38 4.17 > 5.0
* Collected on the 21st day of the menstrual cycle.
SD: standard deviation.
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Table 2. Fasting LH, testosterone, SHBG and FAI of the subjects (S) in mid-follicular phase, late follicular phase and mid-luteal phase
Clinical characteristic Mid-follicular phase(mean ± SD)
late follicular phase
(mean ± SD)
luteal phase
(mean ± SD) p-value
LH (mUI/mL) 5.45 ± 1.68 6.90 ± 1.62 5.61 ± 4.37 NS
Testosterone (nmol/L) 0.90 ± 0.54 1.34 ± 0.47 1.05 ± 0.20 NS
SHBG (nmol/L) 42.45 ± 16.23 47.27 ± 23.71 46.81 ± 15.61 NS
FAI (nmol/L) 2.34 ± 1.49 3.19 ± 1.40 2.41 ± 0.76 NS
SD: standard deviation; NS: non significant.
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Figure 1. LH pulsatility in the three phases of the menstrual cycle. Frequency (p < 0.01) and mean amplitude (p = 0.02). Increase amplitude and pulse duration was not 
significant. 
Testosterone pulsatility
hypothalamus, pituitary and ovary are necessary. The ste-
roidal ovary production is also involved in this process. 
Gonadotrophins have different pattern of secretion 
in men and women since the first day of life (23). Ne-
vertheless, this difference remains in reproductive life 
with stable frequency and amplitude in men (24,25), 
but shows great variability in women (26,27), inclu-
ding ethnic variations (28). This gonadotrophin pul-
satile liberation reflects the influence of the ovarian 
steroidal secretion on the hypothalamus pituitary axis. 
Androgens are crucial factors for normal develop-
ment of female gonadal function (10). There are suffi-
cient data about gonadotrophin pulsatility (27,29,30), 
but much less is seen about testosterone in the litera-
ture. In the present study, LH did show different pulse 
frequency from the studied phases as already registered 
by other authors (26,27).
Healthy young females with ovulatory cycles have 
already been studied to evaluate testosterone pulsatility 
during the menstrual cycle. Multiple samples from each 
patient were collected: 111 samples, 37 in three mens-
trual cycles. There was no difference among the three 
phases in baseline testosterone nor in SHBG. FAI was 
calculated as a mean to analyze bioavailable testostero-
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D7 D12 D21
Figure 2. Testosterone (ng/dL) pulsatility on Day 7, Day 12 and Day 21 of one of the eight subjects. Time expressed in minutes. 
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Figure 3. Testosterone pulsatility in the three phases of the menstrual cycle. No statistical significance in any parameter. 
ne (31), but it also did not show significant difference 
among the three phases. 
By using adequate methodology, it has been shown 
that testosterone, as other hormones involved with re-
productive physiology (27), is secreted in a pulsatile pat-
tern. However, testosterone pulsatility pattern does not 
vary among the three different menstrual cycle phases 
studied: mid-follicular, late follicular and luteal phase. 
Testosterone pulsatility
32
24 24
20 20
16 16
12 12
8 8
28
24
20
16
12
Ho
rm
on
e c
on
ce
nt
ra
tio
n
Ho
rm
on
e c
on
ce
tra
tio
n
Ho
rm
on
e c
on
ce
tra
tio
n
8
4
50 100 150 200 250 300 350 50 100 150 200 250 300 350 50 100 150 200 250 300 350
Time Time Time
C
o
p
yr
ig
h
t©
 A
BE
&
M
 to
d
o
s 
o
s 
d
ire
ito
s 
re
se
rv
a
d
o
s.
1045Arq Bras Endocrinol Metab. 2009;53/8
It should be considered that, during the reproductive 
years, androgens are produced by two sources: ovaries 
and adrenal glands (32), and these are not under LH 
control. In addition, other hormones from ovary and 
adrenal, which production can vary during menstrual 
cycle, can influence in different ways the activated en-
zymatic mechanisms of the follicle and luteolysed cells 
and so could influence testosterone production beyond 
the LH (2). 
Pulsatility studies are usually related to considerable 
difficulty in volunteer’s recruitment. Multiple samples 
are required and total blood loss is a constant preoc-
cupation (20,33). The assay limitation is also impor-
tant as testosterone assays are designed for higher levels 
presented in men and could not be accurate enough 
to determine lower women levels (31,32). In addition, 
serum androgen levels do not necessarily reproduce 
intraovarian androgen concentrations. Further studies 
with assisted reproduction techniques could evaluate 
the correlation between intraovarian androgens and its 
serum pulsatility.
Variations in androgen levels or in its pulsatility 
could contribute to the understanding and manage-
ment of some conditions related to androgen action, 
such as women mood and sexual behavior in the con-
troversial androgen insufficiency syndrome which was 
characterized by a team of investigators in 2002 (34). 
It is well known that testosterone influence behavior 
and both cognitive and sexual function in men (35). 
However, evidence in women is limited by lack of nor-
mative data for androgen levels and much controversy 
relies about types of treatment. As sexual nor mood 
questionnaires were not used, comparison between an-
drogen secretion pattern and possible behavior changes 
in menstrual cycle was not available.
It was shown that there is no variation in testostero-
ne pulsatility during the normal menstrual cycle. This 
physiologic testosterone pulsatility could be compared 
to women with clinical features of the androgen insu-
fficiency syndrome even if baseline androgen levels are 
still normal. Otherwise, testosterone normal pulsatility 
can also be compared to some hyperandrogenic states 
as the polycystic ovarian syndrome (PCOS). Peripheral 
conversion of androgen precursors to active androgens 
may play an important role in androgen action and this 
should influence states of hyperandrogenic diseases. It 
is shown that elevated androgen levels are associated 
with hyperandrogenic features, as acne and hirsutism, 
but there is no evidence to support a relationship be-
tween the degree of androgen elevation and the severi-
ty of these clinical presentations (36). Sometimes, there 
is considerable discrepancy between androgen baseline 
levels and clinical presentation. Expression of andro-
gens receptors in effector organs and hypersensibility of 
end-target organs are usually considered in these cases, 
but variations in testosterone pulsatility could explain 
women presented with hyperandrogenic features and 
normal baseline androgens.
In conclusion, this study presented, for the first 
time, that testosterone is secreted in a pulsatile pattern 
as well as the comparison of this pulsatile profile in dis-
tinct phases of the menstrual cycle without differences 
among them. Additional studies are needed to compare 
normal ovulatory cycles and pathologic cycles, both in 
androgen excess and androgen insufficiency, to define 
if there is any alteration in this pulsatile pattern related 
to hyperandrogenic anovulation or female androgen in-
sufficiency syndrome. 
Disclosure: no potential conflict of interest relevant to this article 
was reported. 
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